• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Tuesday, June 24, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Biomarker for COVID-19 risk

Bioengineer by Bioengineer
April 19, 2021
in Health
Reading Time: 2 mins read
0
ADVERTISEMENT
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Patient inflammation varies for lung, clot reactions

IMAGE

Credit: Flinders University

Varying severity of COVID-19 symptoms in patients is reflected by levels of a chemical biomarker in their body which scientists say could be used to better manage treatments and other interventions, including vaccinations.

In a new paper in International Journal of Infectious Diseases, medical experts in Italy and Australia examined levels of a chemical called serum amyloid A (SAA), a protein synthesised in the liver which can spike up to 1,000-fold within the first 24-48 hours of an infection.

In turn, an increase in SAA can further perpetuate inflammation and cause clot abnormalities and organ damage, researchers say, concluding SAA levels are associated with higher COVID-19 severity and mortality.

The University of Sassari and Flinders University researchers focused on the latest research including 19 studies of more than 5,600 COVID-19 patients for specific markers to predict disease severity and progression.

“Our analyses showed that COVID-19 patients with severe disease or who eventually died had significantly higher levels of SAA when compared to patients with mild COVID-19,” says senior corresponding author Professor of Clinical Pharmacology Arduino Mangoni, from Flinders University in South Australia.

“Patients with severe forms of coronavirus disease 2019 have excessive inflammation, alterations in clot formation, and significant damage in several organs, particularly the lung, the kidney, the heart, and the liver,”

Given the key role of inflammation in COVID-19, markers that reflect a state of excessive inflammation might be particularly useful for risk stratification and effective management.

“This chemical may help, together with other patient characteristics, in predicting which COVID-19 patients are likely to deteriorate and require aggressive management,” the researchers say.

While safe and effective vaccines are being rolled out worldwide there are currently few effective therapies to treat COVID-19 in the community and in hospital.

In this context, the use of specific markers to predict disease severity and would facilitate the early identification of patients requiring aggressive management and monitoring and assist with the judicious use of health care resources.

The link between SAA and COVID-19 severity and mortality focused on data collected from 5,617 patients hospitalised with COVID-10 with different degrees of severity and survival status, along with current literature.

###

The paper, Serum amyloid A concentrations, COVID-19 severity and mortality: An updated systematic review and meta-analysis (2021) by Angelo Zinellu, Panagiotis Paliogiannis, Ciriaco Carru and Arduino A. Mangoni has been published in there International Journal of Infectious Diseases DOI: 10.1016/j.ijid.2021.03.025

Media Contact
Professor Arduino Mangoni
[email protected]

Related Journal Article

http://dx.doi.org/10.1016/j.ijid.2021.03.025

Tags: BiochemistryCritical Care/Emergency MedicineDeath/DyingEndocrinologyInfectious/Emerging DiseasesMedicine/HealthVaccines
Share12Tweet8Share2ShareShareShare2

Related Posts

Metabolic Messengers: The Role of Oestradiol

Metabolic Messengers: The Role of Oestradiol

June 24, 2025
blank

HSV1 Glycoprotein D Blocks Alpha7 Nicotinic Receptors

June 24, 2025

Deep Learning Predicts Walking Forces with Knee Alignment

June 24, 2025

Robotic Intubation and AI Airway Tech

June 24, 2025
Please login to join discussion

POPULAR NEWS

  • Green brake lights in the front could reduce accidents

    Study from TU Graz Reveals Front Brake Lights Could Drastically Diminish Road Accident Rates

    161 shares
    Share 64 Tweet 40
  • Pancreatic Cancer Vaccines Eradicate Disease in Preclinical Studies

    72 shares
    Share 29 Tweet 18
  • Enhancing Broiler Growth: Mannanase Boosts Performance with Reduced Soy and Energy

    66 shares
    Share 26 Tweet 17
  • How Scientists Unraveled the Mystery Behind the Gigantic Size of Extinct Ground Sloths—and What Led to Their Demise

    65 shares
    Share 26 Tweet 16

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Cell Therapy Enhances Survival Rates in Colorectal Cancer Patients

Metabolic Messengers: The Role of Oestradiol

Pulmonary T2* MRI: New Fetal Lung Assessment Tool?

  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.